ArticleFrontiers in nutrition2023
Association of antioxidants use with the risk of dementia among community-dwelling adults in the United Kingdom biobank.
Article in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Identification of a Four-Gene Signature Based on Metal Metabolism for Alzheimer's Disease Diagnosis.Genes · 2025Article
- Association of zinc deficiency and risk of new-onset dementia: a retrospective cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data regarding the association between antioxidant supplementation and incident dementia are limited. Methods: We included 494,632 adults (54.5% females) aged 40-71 years at baseline from the United Kingdom Biobank in the final analysis. Incident dementia was ascertained using hospital inpatient and death records up to January 2021. Results: Over a median follow-up of 11.9 years, 7,128 new cases of all-cause dementia, 2,772 cases of Alzheimer's disease, and 1,397 cases of vascular dementia were recorded. The hazard ratio (95% CI) for incident dementia associated with zinc supplementation was 0.84 (0.74-0.96), and the association remained significant after adjusting for all confounders (0.84 (0.74-0.96)). In the full model, zinc supplementation was associated with a reduced risk of Alzheimer's disease [HR (95% CI): 0.71 (0.57-0.88)]. There was no significant association between zinc supplementation and the risk of vascular dementia. No significant associations with incident dementia were observed for other antioxidant supplementation. The association between zinc supplementation and incident dementia was significant among individuals with [HR (95% CI): 0.34 (0.15-0.77)] and without cataract [0.87 (0.77-0.99)] but it was stronger among those with cataract ( Conclusion: Our findings suggest that zinc supplementation may help reduce the risk of all-cause dementia and Alzheimer's disease in middle-aged or older adults, especially among those with cataracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.